Molecular targeted approaches for treatment of pancreatic cancer

Current Pharmaceutical Design

Volumn 17, Issue 21, 2011, Pages 2221-2238

  Huang, Z Q ^a   Saluja, A K ^b   Dudeja, V ^b   Vickers, S M ^b   Buchsbaum, D J ^a  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Drug resistance; Gene therapy; Kinase inhibitors; Molecular targeted therapy; Monoclonal antibody; Pancreatic ductal adenocarcinoma; Pancreatic stroma

Indexed keywords

ALGENPANTUCEL; BC 819; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CL 4047; CONDITIONALLY REPLICATING ADENOVIRUS; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FOLINIC ACID; GEMCITABINE; GENE THERAPY AGENT; GRN 163 L; HEAT SHOCK PROTEIN; IMETELSTAT; IMMUNOLOGIC AGENT; IRINOTECAN; MATUZUMAB; MESOTHELIN; MUCIN; OXALIPLATIN; PHOSPHOTRANSFERASE INHIBITOR; POMALIDOMIDE; REOLYSIN; REXIN G; SOMATOMEDIN C RECEPTOR; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

BLOOD FLOW; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG SENSITIVITY; GENE THERAPY; GENOMICS; HYPOXIA; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; METASTASIS; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; STROMA CELL; T LYMPHOCYTE ACTIVATION; TUMOR BIOPSY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 80052195100     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796957427     Document Type: Review

References (206)

1. Ellison LF, Wilkins K. An update on cancer survival, Health Rep, 2010, 21: 55-60.
2. Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer, Br J Surg, 2004, 91: 1410-27.
3. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?, Lancet Oncol, 2011, 12: 8-9.
4. Joseph I, Tressler R, Bassett E, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines, Cancer Res, 2010, 70: 9494-504.
5. Kelleher FC. Hedgehog signalling and therapeutics in pancreatic cancer, Carcinogenesis, 2011, 32: 445-51.
6. Azmi AS, Wang Z, Philip PA, et al. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations, Mol Cancer Ther, 2010, 9: 3137-44.
7. Kern SE, Shi C, Hruban RH. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting, J Pathol, 2011, 223: 295-306.
8. Cunningham D, Chong I. Optimal treatment of metastatic pancreatic cancer, Gut, 2010, 59: 1454-5.
9. McClean MN, Mody A, Broach JR, et al. Cross-talk and decision making in MAP kinase pathways, Nat Genet, 2007, 39: 409-14.
10. Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res, 2011, 17: 6-11.
11. Rhim AD. A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?, Cancer Biol Ther, 2009, 8: 1902-3.
12. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/ insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer, Clin Cancer Res, 2010, 16: 2505-11.
13. Kisfalvi K, Eibl G, Sinnett-Smith J, et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth, Cancer Res, 2009, 69: 6539-45.
14. Lopez-Otin C, Hunter T. The regulatory crosstalk between kinases and proteases in cancer, Nat Rev Cancer, 2010, 10: 278-92.
15. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 2011, 364: 1817-25.
16. Fujita H, Ohuchida K, Mizumoto K, et al. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy, Int J Oncol, 2011, 38: 629-41.
17. Huang Z-q, Buchsbaum DJ, Raisch KP, et al. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody, J. Surg. Res., 2003, 111: 274-83.
18. Morgan MA, Parsels LA, Kollar LE, et al. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer, Clin Cancer Res, 2008, 14: 5142-9.
19. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial, Lancet Oncol, 2008, 9: 39-44.
20. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Groupdirected intergroup trial S0205, J Clin Oncol, 2010, 28: 3605-10.
21. [PA, Goldman BH, Ramanathan RK, et al. SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer, J Clin Oncol, 2010, 28: Abstract TPS 223.
22. [J, Catalano P, Feng Y, et al. ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC), J Clin Oncol, 2010, 28: Abstract 4034.
23. Rocha Lima CS, Lin EH, Kim G, et al. Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC)., J Clin Oncol, 2010, 28: Abstract 4086.
24. Kleespies A, Ischenko I, Eichhorn ME, et al. Matuzumab shortterm therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine, Clin Cancer Res, 2008, 14: 5426-36.
25. Saif MW, Peccerillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature, Cancer Chemother Pharmacol, 2009, 63: 1017-22.
26. [D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer, Invest New Drugs, 2010 [Epub ahead of print].
27. Tsiambas E, Karameris A, Dervenis C, et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis, JOP, 2006, 7: 283-94.
28. Komoto M, Nakata B, Amano R, et al. HER2 overexpression correlates with survival after curative resection of pancreatic cancer, Cancer Sci, 2009, 100: 1243-7.
29. Chaturvedi P, Singh AP, Chakraborty S, et al. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells, Cancer Res, 2008, 68: 2065-70.
30. Saeki H, Yanoma S, Takemiya S, et al. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer, Oncol Rep, 2007, 18: 433-9.
31. Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine, Clin Cancer Res, 2006, 12: 4925-32.
32. [M, Hofheinz R, Meoehler MH, et al. Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204)., J Clin Oncol, 2010, 28: Abstract 4070.
33. [A, Perez-Torras S, Miquel R, et al. Targeted therapy to EGFR and HER2 combined with gemcitabine in a novel human pancreatic orthotopic model, Journal of Clinical Oncology, 2010, 28: Abstract e14601.
34. Milenic DE, Wong KJ, Baidoo KE, et al. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials, MAbs, 2010, 2: 550-64.
35. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer, J Clin Oncol, 2005, 23: 2534-43.
36. Aggarwal BB, Bhardwaj U, Takada Y. Regulation of TRAILinduced apoptosis by ectopic expression of antiapoptotic factors, Vitam Horm, 2004, 67: 453-83.
37. Debatin K-M, Krammer PH. Death receptors in chemotherapy and cancer, Oncogene, 2004, 23: 2950-66.
38. Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie?, Cell, 2004, 116: 491-7.
39. Rudner J, Jendrossek V, Lauber K, et al. Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies, Oncogene, 2005, 24: 130-40.
40. Buchsbaum DJ, Zhou T, LoBuglio AF. TRAIL receptor-targeted therapy, Future Oncol., 2006, 2: 493-508.
41. Yada A, Yazawa M, Ishida S, et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes, Ann Oncol, 2008, 19: 1060-7.
42. Amm HM, Oliver PG, Lee CH, et al. Combined modality therapy with TRAIL or agonistic death receptor antibodies, Cancer Biol Ther, 2011, 11: 431-49.
43. DeRosier LC, Vickers SM, Zinn KR, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth, Mol. Cancer Ther., 2007, 6: 3198-207.
44. [LC, Buchsbaum DJ, Oliver PG, et al. Combination treatment with TRA-8 anti-death receptor-5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer, Clin. Cancer Res., 2007, 13: 5535s-43s.
45. Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model, Mol Cancer Ther, 2010, 9: 2582-92.
46. Rosevear HM, Lightfoot AJ, Griffith TS. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer, Curr Opin Investig Drugs, 2010, 11: 688-98.
47. Herbst RS, Kurzrock R, Hong DS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors, Clin Cancer Res, 2010, 16: 5883-91.
48. Doi T, Murakami H, Ohtsu A, et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors, Cancer Chemother Pharmacol, 2011 [Epub ahead of print].
49. Adams C, Totpal K, Lawrence D, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5, Cell Death Differ, 2008, 15: 751-61.
50. Punnoose E, Wagner K, Lamler L, et al. Sensitivity to Apomab, an agonistic DR5 specific antibody, is correlated with expression of specific O-glycosyl transfereases in tumor-cell lines of both epithelial and non epithelial origin, Proc. Am. Assoc. Cancer Res., 2009, Apr 18-22, abstract 687.
51. Neid M, Datta K, Stephan S, et al. Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/ vascular endothelial growth factor expression in pancreatic cancer cells, J Biol Chem, 2004, 279: 3941-8.
52. Liu W, Bloom DA, Cance WG, et al. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells, Carcinogenesis, 2008, 29: 1096-107.
53. Ma J, Sawai H, Matsuo Y, et al. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells, J Surg Res, 2010, 160: 90-101.
54. Adachi Y, Li R, Yamamoto H, et al. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin, Carcinogenesis, 2009, 30: 1305-13.
55. Tomizawa M, Shinozaki F, Sugiyama T, et al. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer, World J Gastroenterol, 2010, 16: 1854-8.
56. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF, et al. Insulin is a potent myeloma cell growth factor through insulin/ IGF-1 hybrid receptor activation, Leukemia, 2010, 24: 1940-50.
57. Ulanet DB, Ludwig DL, Kahn CR, et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy, Proc Natl Acad Sci USA, 2010, 107: 10791-8.
58. [Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor, Clin Cancer Res, 2007, 13: 5549s-55s.
59. Prewett M, Damoci C, Bassi R, et al. IMC-A12 enhances the efficacy of cetuximab + gemcitabine therapy in human pancreatic carcinoma xenografts, AACR Meeting Abstracts, 2007, 2007: 652.
60. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells, Mol Cancer Ther, 2009, 8: 1095-105.
61. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1, J Clin Oncol, 2009, 27: 5800-7.
62. Li JC, Li R. RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205, Cancer Res, 2007, 67: 8856-64.
63. Loo D, Pryer N, Young P, et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo, Mol Cancer Ther, 2007, 6: 856-65.
64. Burris HA, Rosen LS, Rocha-Lima CM, et al. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma, Clin Cancer Res, 2010, 16: 1673-81.
65. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human antitype 1 insulin-like growth factor receptor monoclonal antibody CP-751,871, Clin Cancer Res, 2005, 11: 2063-73.
66. Runnels HA, Arbuckle JA, Bailey KS, et al. Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies, Adv Ther, 2010, 27: 458-75.
67. [Watkins DJ, Tabernero J, Schmoll HJ, et al. A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer., J Clin Oncol, 2009, 27: Abstract 4127.
68. [Javie MM, Varadhachary GR, Shroff RT, et al. Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer., J Clin Oncol, 2010, 28: Abstract 4039.
69. Carboni JM, Wittman M, Yang Z, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR, Mol Cancer Ther, 2009, 8: 3341-9.
70. Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis, Am J Clin Pathol, 2005, 124: 838-45.
71. Hucl T, Brody JR, Gallmeier E, et al. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif, Cancer Res, 2007, 67: 9055-65.
72. Hassan R, Williams-Gould J, Steinberg SM, et al. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin- expressing tumor xenografts, Clin Cancer Res, 2006, 12: 4983-8.
73. Hassan R, Broaddus VC, Wilson S, et al. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts, Clin Cancer Res, 2007, 13: 7166-71.
74. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers, Clin Cancer Res, 2007, 13: 5144-9.
75. Kreitman RJ, Hassan R, Fitzgerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P, Clin Cancer Res, 2009, 15: 5274-9.
76. Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin, Cancer Immun, 2007, 7: 20.
77. Feng Y, Xiao X, Zhu Z, et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity, Mol Cancer Ther, 2009, 8: 1113-8.
78. Levi E, Klimstra DS, Andea A, et al. MUC1 and MUC2 in pancreatic neoplasia, J Clin Pathol, 2004, 57: 456-62.
79. [Patel KN, Maghami E, Wreesmann VB, et al. MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas, Surgery, 2005, 138: 994-1001, discussion -2.
80. Zaretsky JZ, Barnea I, Aylon Y, et al. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expression, Mol Cancer, 2006, 5: 57.
81. Yamada N, Nishida Y, Tsutsumida H, et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells, Cancer Res, 2008, 68: 2708-16.
82. Swanson BJ, McDermott KM, Singh PK, et al. MUC1 is a counterreceptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion, Cancer Res, 2007, 67: 10222-9.
83. Kohlgraf KG, Gawron AJ, Higashi M, et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line, Cancer Res, 2003, 63: 5011-20.
84. Roy LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition, Oncogene, 2011, 30: 1449-59.
85. Ahmad R, Raina D, Trivedi V, et al. MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-IκB signalling, Nat Cell Biol, 2007, 9: 1419-27.
86. Agata N, Ahmad R, Kawano T, et al. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8, Cancer Res, 2008, 68: 6136-44.
87. Yuan Z, Wong S, Borrelli A, et al. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting Ecadherin/ catenin complex formation, Biochem Biophys Res Commun, 2007, 362: 740-6.
88. Yuan Z, Liu X, Wong S, et al. MUC1 Knockdown With RNA Interference Inhibits Pancreatic Cancer Growth, J Surg Res, 2009, 157: e39-46.
89. Gulec SC, Cohen SJ, Zuckier LS, et al. First clinical experience with 90Y-radiolabeled humanized anti-MUC1 antibody (hPAM4) in patients with advanced pancreatic cancer: A phase I study, J. Clin. Oncol., 2007, 25: 15034.
90. Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma, Cancer Res, 2008, 68: 4819-26.
91. Karacay H, Sharkey RM, Gold DV, et al. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine, J Nucl Med, 2009, 50: 2008-16.
92. Glazer ES, Zhu C, Massey KL, et al. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles, Clin Cancer Res, 2010, 16: 5712-21.
93. Baranowska-Kortylewicz J, Abe M, Nearman J, et al. Emerging role of platelet-derived growth factor receptor-β inhibition in radioimmunotherapy of experimental pancreatic cancer, Clin Cancer Res, 2007, 13: 299-306.
94. [Mita M, Ricart A, Mita A, et al. A phase I study of a CanAgtargeted immunoconjugate, huC242-DM4, in patients with CanAgexpressing solid tumors, J Clin. Oncol., 2007, 25: Abstract 3062.
95. Govindan SV, Cardillo TM, Moon SJ, et al. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates, Clin Cancer Res, 2009, 15: 6052-61.
96. Safran H, Miner T, Resnick M, et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer, Am J Clin Oncol, 2008, 31: 140-4.
97. Stieler J, Pelzer U, Sinn M, et al. CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial., J Clin Oncol, 2010, 28: Abstract TPS225.
98. El-Rayes BF, Philip PA, Sarkar FH, et al. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer, Invest New Drugs, 2011, 29: 694-9.
99. [Keogh GP, Langdon RM, Stella PJ, et al. APRICoT-P: A phase II randomized placebo controlled study of apricoxib, a potent COX-2 inhibitor in combination with erlotinib and gemcitabine in pancreatic cancer patients., J Clin Oncol, 2010, 28: Abstract TPS224.
100. [Boeck SH, Vehling-Kaiser U, Waldshmidt D, et al. Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol, 2010, 28: Abstract LBA4011.
101. Ko AH, Venook AP, Bergsland EK, et al. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer, Cancer Chemother Pharmacol, 2010, 66: 1051-7.
102. [Watkins DJ, Starling N, Chau I, et al. The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study, J Clin Oncol, 2010, 28: Abstract 4036.
103. [Manzano J, Rivera F, Galan M, et al. A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine, J Clin Oncol, 2010, 28: Abstract 4094.
104. [Milella M, Vaccaro V, Sperduti I, et al. Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC), J Clin Oncol, 2010, 28: Abstract e14565.
105. [Vickers MM, Powell ED, Asmis TR, et al. Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone., J Clin Oncol, 2010, 28: Abstract 4079.
106. [Stuebs P, Habermann P, Zierau K, et al. First-line therapy for advanced pancreatic cancer with gemcitabine and docetaxel versus gemcitabine and erlotinib: A multivariate matched pair analysis, J Clin Oncol, 2010, 28: Abstract e14572.
107. [Jiang Y, Kimchi E, Gusani NJ, et al. Phase I study of capecitabine and erlotinib with radiotherapy in locally advanced nonoperable pancreatic cancer., J Clin Oncol, 2010, 28: Abstract e14680.
108. [Javle M, Reddy S, Davis D, et al. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer - the results of two prospective phase II studies., Proc Am Assoc Cancer Res, 2009: Abstract 4363.
109. Jeldres C, Sun M, Perrotte P, Karakiewicz PI. Pazopanib trial data cannot support first-line use, Nat Rev Urol, 2010, 7: 307-8.
110. Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors, Oncologist, 2010, 15: 1253-61.
111. Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study, Lancet, 2008, 371: 2101-8.
112. Starling N, Hawkes EA, Chau I, et al. A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC). J Clin Oncol, 2010, 28: Abstract 4155.
113. Garrido-Laguna I, Tan AC, Uson M, et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer, Br J Cancer, 2010, 103: 649-55.
114. Javle MM, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies, BMC Cancer, 2010, 10: 368.
115. Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies, Clin Cancer Res, 2009, 15: 7061-8.
116. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2, Clin Cancer Res, 2010, 16: 3507-16.
117. [WA, Nallapareddy S, Arcaroli J, et al. A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer. Print this page J Clin Oncol, 2010, 28: Abstract e14515.
118. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 2007, 25: 1960-6.
119. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy, J Hematol Oncol, 2009, 2: 45.
120. [O'Reilly T, McSheehy PMJ, Brueggen J, et al. In vivo antitumor activity of RAD001 (everolimus) in 58 specialized human tumor xenograft models, Proc Am Assoc Cancer Res, 2008: Abstract 2917.
121. [H, Jensen M. Inhibitory effect of pasireotide (SOM230) in a rat pancreatic tumor model (CA20948) alone and in combination with everolimus (RAD001), Proc Am Assoc Cancer Res, 2009: Abstract 808.
122. Chang Q, Chapman MS, Miner JN, et al. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts, BMC Cancer, 2010, 10: 515.
123. Clark A, Ma JG, Qiu D, et al. Pharmacokinetics, efficacy and target pathway inhibition in vivo of AS703026, a small molecule inhibitor of MEK, Proc Am Assoc Cancer Res, 2009: Abstract 3694.
124. [Machl A, Ogden j, Romanelli A. Efficacy of MEK inhibitor AS703026 in various primary tumor explants., Proc Am Assoc Cancer Res, 2009 Apr 18-22, Denver, CO. Philadelphia (PA): AACR, 2009. Abstract nr 3698., 2009.
125. Ulivi P, Arienti C, Tesei A, et al. Different mechanisms involved in the activity of BAY 43-9006 (Sorafenib) in human pancreatic cancer cell lines, Proc Am Assoc Cancer Res, 2008: Abstract 2809.
126. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells, Mol Cancer Ther, 2010, 9: 742-50.
127. Shi H, Liu L, Greger J, et al. GSK1363089 inhibits MET and synergizes with HER targeted agents in MET amplified/overexpressed and HER1/HER2 amplified tumor cells, Proc Am Assoc Cancer Res, 2009: Abstract 1746.
128. [Kindler HL, Wroblewski K, Wallace JA, et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium, Invest New Drugs, 2010 [Epub ahead of print].
129. Yeatman TJ. A renaissance for SRC, Nat Rev Cancer, 2004, 4: 470-80.
130. Nagaraj NS, Smith JJ, Revetta F. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis, Mol Cancer Ther, 2010, 9: 2322-32.
131. Nagaraj NS, Washington MK, Merchant NB. Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth, Clin Cancer Res, 17: 483-93.
132. Evans T, Morton J, Karim S, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic cancer, Proc Am Assoc Cancer Res, 2009 Apr 18-22, Denver, CO. Philadelphia (PA): AACR, 2009. Abstract nr LB-217., 2009.
133. Chang Q, Jorgensen C, Pawson T, et al. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer, Br J Cancer, 2008, 99: 1074-82.
134. Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, et al. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer, Invest New Drugs, 2010 [Epub ahead of print].
135. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer, Gut, 2011, 60: 861-8.
136. Xu Z, Vonlaufen A, Phillips PA, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis, Am J Pathol, 2010, 177: 2585-96.
137. Ikenaga N, Ohuchida K, Mizumoto K, et al. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer, Gastroenterology, 2010, 139: 1041-51, 51 e1-8.
138. Xu D, Matsuo Y, Ma J, et al. Cancer cell-derived IL-1alpha promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells, J Surg Oncol, 2010, 102: 469-77.
139. Garber K. Stromal depletion goes on trial in pancreatic cancer, J Natl Cancer Inst, 2010, 102: 448-50.
140. Hooper JE, Scott MP. Communicating with Hedgehogs, Nat Rev Mol Cell Biol, 2005, 6: 306-17.
141. Steg A, Amm HM, Novak Z, et al. Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer, Cancer Biol Ther, 2010, 10: 893-902.
142. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis, Nature, 2003, 425: 851-6.
143. Walter K, Omura N, Hong SM, et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts, Clin Cancer Res, 2010, 16: 1781-9.
144. Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis, Proc Natl Acad Sci USA, 2009, 106: 4254-9.
145. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane, Expert Opin Pharmacother, 2006, 7: 1041-53.
146. Iglesias J. nab-Paclitaxel (Abraxane®): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors, Breast Cancer Res, 2009, 11 Suppl 1: S9.
147. Clark CJ, Sage EH. A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire, J Cell Biochem, 2008, 104: 721-32.
148. Mantoni TS, Schendel RR, Rodel F, et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma, Cancer Biol Ther, 2008, 7: 1806-15.
149. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma, J Clin Oncol, 2007, 25: 319-25.
150. Miyoshi K, Sato N, Ohuchida K, et al. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients, Anticancer Res, 2010, 30: 867-71.
151. Gao J, Song J, Huang H, et al. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer, J Exp Clin Cancer Res, 2010, 29: 28.
152. [Hosein PJ, Lopes Jr. GD, Gomez CM, et al. A phase II trial of nabpaclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy, J Clin Oncol, 2010, 28: Abstract 4120.
153. [Thapaliya P, Kundranda MN, Curtis KK, et al. Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer, J Clin Oncol, 2010, 28: Abstract e14675.
154. [Isacoff WH, Reber HA, Purcell FM, Clerkin BM, Clerkin KM. Low-dose continuous infusion 5-fluorouracil combined with weekly leucovorin, nab-paclitaxel, oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: A pilot study. J Clin Oncol, 2010, 28: Abstract e14545.
155. Shojaei F, Ferrara N. Antiangiogenic therapy for cancer: an update, Cancer J, 2007, 13: 345-8.
156. Beckermann BM, Kallifatidis G, Groth A, et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma, Br J Cancer, 2008, 99: 622-31.
157. Zhang B, Zhao WH, Zhou WY, et al. Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma, Cancer Detect Prev, 2007, 31: 436-42.
158. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis, JAMA, 2011, 305: 487-94.
159. Lorusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors, Clin Cancer Res, 2011, 17: 2502-11.
160. Chien AJ, Illi JA, Ko AH, et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albuminbound Paclitaxel for advanced solid malignancies, Clin Cancer Res, 2009, 15: 5569-75.
161. [Martin L, Li X, Kim S, et al. A multi-center phase II study of the combination of bevacizumab, fixed dose rate gemcitabine, and infusional 5-fluorouracil in patients with advanced pancreas cancer, Proc Am Assoc Cancer Res, 2009: Abstract 4500.
162. Garrido C, Brunet M, Didelot C, et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties, Cell Cycle, 2006, 5: 2592-601.
163. Aghdassi A, Phillips P, Dudeja V, et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma, Cancer Res, 2007, 67: 616-25.
164. Dudeja V, Chugh RK, Sangwan V, et al. Pro-survival Role of Heat Shock Factor 1 (HSF1) in the Pathogenesis of PancreatoBiliary Tumors, Am J Physiol Gastrointest Liver Physiol, 2011, 300: G948-G55.
165. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 in hepatocellular carcinoma, J Korean Med Sci, 2005, 20: 829-34.
166. Wang XP, Qiu FR, Liu GZ, et al. Correlation between clinicopathology and expression of heat shock protein 70 and glucoseregulated protein 94 in human colonic adenocarcinoma, World J Gastroenterol, 2005, 11: 1056-9.
167. Phillips PA, Dudeja V, McCarroll JA, et al. Triptolide Induces Pancreatic Cancer Cell Death via Inhibition of Heat Shock Protein 70, Cancer Res, 2007, 67: 9407-16.
168. Westerheide SD, Kawahara TL, Orton K, et al. Triptolide, an inhibitor of the human heat shock response that enhances stressinduced cell death, J Biol Chem, 2006, 281: 9616-22.
169. Borja-Cacho D, Yokoyama Y, Chugh RK, et al. TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells, J Gastrointest Surg, 2010, 14: 252-60.
170. Nylandsted J, Brand K, Jaattela M. Heat shock protein 70 is required for the survival of cancer cells, Ann N Y Acad Sci, 2000, 926: 122-5.
171. Sherman M, Multhoff G. Heat shock proteins in cancer, Ann N Y Acad Sci, 2007, 1113: 192-201.
172. Antonoff MB, Chugh R, Borja-Cacho D, et al. Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo, Surgery, 2009, 146: 282-90.
173. Clawson KA, Borja-Cacho D, Antonoff MB, et al. Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma, J Surg Res, 2010, 163: 244-9.
174. Lippert TH, Ruoff HJ, Volm M. Current status of methods to assess cancer drug resistance, Int J Med Sci, 2011, 8: 245-53.
175. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer, Mol Cancer Ther, 2011, 10: 3-8.
176. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development, Science, 1999, 284: 770-6.
177. Mysliwiec P, Boucher MJ. Targeting Notch signaling in pancreatic cancer patients--rationale for new therapy, Adv Med Sci, 2009, 54: 136-42.
178. Mazur PK, Einwachter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma, Proc Natl Acad Sci USA, 2010, 107: 13438-43.
179. Wang Z, Li Y, Kong D, et al. Acquisition of epithelialmesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway, Cancer Res, 2009, 69: 2400-7.
180. Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Aktdependent pathway, Med Oncol, 2010, 27: 1017-22.
181. [Singh S, Srivastava SK, Bhardwaj A, et al. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy, Br J Cancer, 103: 1671-9.
182. Hagmann W, Jesnowski R, Lohr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells, Neoplasia, 12: 740-7.
183. [Nambaru PK, Hubner T, Kock K, et al. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5- fluorouracil, Drug Metab Dispos, 39: 132-9.
184. Tanaka M, Okazaki T, Suzuki H, et al. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome, Cancer, 117: 744-51.
185. Kalra AV, Campbell RB. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours, Eur J Cancer, 2009, 45: 164-73.
186. Li Z, Dong Z, Myer D, Yip-Schneider M, Liu J, Cui P, et al. Role of 14-3-3sigma in poor prognosis and in radiation and drug resistance of human pancreatic cancers, BMC Cancer, 10: 598.
187. [Ramachandran K, Miller H, Gordian E, et al. Methylationmediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity, Anticancer Res, 30: 3919-25.
188. Siraj AK, Hussain AR, Al-Rasheed M, et al. Demethylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis, J Clin Endocrinol Metab, 96: E215-24.
189. [Mazur PK, Einwachter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma, Proc Natl Acad Sci USA, 107: 13438-43.
190. Wang Z, Li Y, Ahmad A, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy, Biochim Biophys Acta, 1806: 258-67.
191. Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Aktdependent pathway, Med Oncol, 27: 1017-22.
192. Smith JK, Ng S, Simons JP, et al. Adjuvant therapy for resectable pancreatic cancer: A simple prediction rule, ASCO - 2010 Gastrointestinal Cancers Symposium, 2010: Abstract 236.
193. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies, Cancer, 2007, 110: 2614-27.
194. Loos M, Giese NA, Kleeff J, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer, Cancer Lett, 2008, 268: 98-109.
195. Aglietta M, Barone C, Muliello M, et al. A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer, J Clin Oncol, 2010, 28: Abstract 4134.
196. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J Immunother, 2010, 33: 828-33.
197. Li S, Gill N, Lentzsch S. Recent advances of IMiDs in cancer therapy, Curr Opin Oncol, 2010, 22: 579-85.
198. Infante JR, Jones SF, Bendell JC, et al. A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer, Eur J Cancer, 2011, 47: 199-205.
199. Scaiewicz V, Sorin V, Fellig Y, et al. Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer, J Oncol, 2010 [Epub ahead of print], 2010: 178174.
200. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers, Curr Opin Mol Ther, 2010, 12: 607-16.
201. Galanis E, Carlson SK, Foster NR, et al. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer, Mol Ther, 2008, 16: 979-84.
202. Gordon EM, Hall FL. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent, Int J Oncol, 2010, 36: 1341-53.
203. Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors, Invest New Drugs, 2010, 28: 641-9.
204. Nelson AR, Davydova J, Curiel DT, et al. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer, Cancer Sci, 2009, 100: 2181-7.
205. Murugesan SR, King CR, Osborn R, et al. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer, Cancer Gene Ther, 2009, 16: 841-7.
206. Mohr A, Albarenque SM, Deedigan L, et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells, Stem Cells, 2010, 28: 2109-20.